Oligohydrosis and fever in pediatric patients treated with zonisamide

• Published in: Pediatric neurology 2003-03, Vol.28 (3), p.184-189
• Main Authors: Knudsen, James F., Thambi, Lopa R., Kapcala, Leonard P., Racoosin, Judith A.
• Format: Article
• Language: English
• Subjects: Adolescent; Adverse Drug Reaction Reporting Systems - statistics & numerical data; Biological and medical sciences; Child; Child, Preschool; Drug toxicity and drugs side effects treatment; Female; Fever - chemically induced; Humans; Hypohidrosis - chemically induced; Infant; Isoxazoles - adverse effects; Male; Medical sciences; Pharmacology. Drug treatments; Toxicity: skin, dermoskeleton; Zonisamide
• ISSN: 0887-8994; 1873-5150
• DOI: 10.1016/S0887-8994(02)00511-8

Zonisamide is an antiepileptic drug developed and first marketed in Japan in 1989. Cases of oligohydrosis, characterized by deficient production and secretion of sweat, were reported in children treated with zonisamide in Japan during development and in the postmarketing period. Zonisamide was approved in the United States in March 2000 for adjunctive treatment of partial seizures in adults. Searching the Food and Drug Administration’s Adverse Events Reporting System, we identified six domestic cases of zonisamide-associated oligohydrosis and/or fever, all in patients ≤ 18 years of age. The calculated reporting rate was 13 cases per 10,000 pediatric-years of exposure, approximately 10–fold the reporting rate in Japan. A possible risk factor for the development of oligohydrosis in these cases was pediatric age, leading to exposure to elevated zonisamide blood levels relative to patient size. Although the mechanism for zonisamide-associated oligohydrosis has not been fully elucidated, the drug may mediate its effect on eccrine sweat glands by inhibiting carbonic anhydrase, thereby influencing pH dynamics, hydrogen ion concentration, and available calcium transients. Awareness of zonisamide-associated oligohydrosis may prevent morbidity, especially in the pediatric population.